New study tracks brain and energy side effects of prostate cancer meds

NCT ID NCT07181122

Recruiting now Knowledge-focused Sponsor: Ankara Etlik City Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 102 men with metastatic hormone-sensitive prostate cancer who are taking standard drugs (abiraterone, apalutamide, enzalutamide, or darolutamide) plus hormone therapy. Researchers will check thinking skills, fatigue, mood, and sleep at the start, 3 months, and 6 months using simple questionnaires. The goal is to see how these treatments affect daily life and mental function in the real world.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Androgen receptor pathway inhibitors (abiraterone, apalutamide, enzalutamide, darolutamide)
What this could lead to: If successful, this study could help doctors understand how these drugs affect thinking, energy, and mood, leading to better support for patients.
What could go wrong: This is an observational study, not a treatment trial. It only measures outcomes without testing a new therapy, so it won't directly improve treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Depression Fatigue insomnia metastatic prostate carcinoma prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)

Contacts and locations

Locations

Etlik City Hospital Medical Oncology Department
RECRUITING

Ankara, Yenimahalle, 06270, Turkey (Türkiye)
Gazi University Medical Oncology Department
RECRUITING

Ankara, Çankaya, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.